These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19719455)

  • 1. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
    Coleman R
    Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in bone-targeted therapies of metastatic prostate cancer.
    Deng X; He G; Liu J; Luo F; Peng X; Tang S; Gao Z; Lin Q; Keller JM; Yang T; Keller ET
    Cancer Treat Rev; 2014 Jul; 40(6):730-8. PubMed ID: 24767837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-targeting agents in prostate cancer.
    Suzman DL; Boikos SA; Carducci MA
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):619-28. PubMed ID: 24398856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone metabolism and new targets for intervention.
    Akduman B; Crawford ED
    Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel bone-targeting agents in prostate cancer.
    Albany C; Hahn NM
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):112-8. PubMed ID: 24662963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal sequence of bone target drugs in metastatic prostatic cancer.
    Gernone A; Bordonaro S; Tralongo P
    Expert Rev Anticancer Ther; 2015; 15(8):923-9. PubMed ID: 26070344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of targeted drug delivery system for the treatment of bone metastasis.
    Vinay R; KusumDevi V
    Drug Deliv; 2016; 23(1):21-9. PubMed ID: 24839990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
    Buijs JT; Kuijpers CC; van der Pluijm G
    Curr Pharm Des; 2010; 16(27):3015-27. PubMed ID: 20722621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.
    Quayle L; Ottewell PD; Holen I
    Curr Cancer Drug Targets; 2015; 15(6):469-80. PubMed ID: 25968899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
    Park SH; Keller ET; Shiozawa Y
    Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.
    Kroon J; Buijs JT; van der Horst G; Cheung H; van der Mark M; van Bloois L; Rizzo LY; Lammers T; Pelger RC; Storm G; van der Pluijm G; Metselaar JM
    Prostate; 2015 Jun; 75(8):815-24. PubMed ID: 25663076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.